Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Kilpatrick

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Clinics in Laboratory Medicine|July 20, 2010
Noninvasive prenatal diagnosis: 2010Mark I Evans, Michael Kilpatrick
Current Opinion in Drug Discovery & Development|December 18, 2004
Purine nucleoside phosphorylase inhibitors in T-cell malignanciesShanta Bantia, John Michael Kilpatrick
Nucleosides, Nucleotides & Nucleic Acids|January 28, 2006
Synthesis and pharmacokinetic and pharmacodynamic evaluation of the forodesine HCl analog BCX-3040Hollis S Kezar, J Michael Kilpatrick, Deborah Phillips, et al.
International Immunopharmacology|April 20, 2010
Potent orally bioavailable purine nucleoside phosphorylase inhibitor BCX-4208 induces apoptosis in B- and T-lymphocytes--a novel treatment approach for autoimmune diseases, organ transplantation and hematologic malignanciesShanta Bantia, Cynthia Parker, Ramanda Upshaw, et al.
International Immunopharmacology|April 12, 2003
Intravenous and oral pharmacokinetic study of BCX-1777, a novel purine nucleoside phosphorylase transition-state inhibitor. In vivo effects on blood 2'-deoxyguanosine in primatesJ Michael Kilpatrick, Philip E Morris, David G Serota, et al.
AJNR. American Journal of Neuroradiology|April 17, 2025
Remote Robotic Neurointervention: Overcoming Procedural and Connectivity ChallengesGary R Duckwiler, Charles B Beaman, Michael Kilpatrick, et al.
Blood|April 30, 2010
Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemiaKumudha Balakrishnan, Dushyant Verma, Susan O'Brien, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Clinics in Laboratory Medicine|July 20, 2010
Noninvasive prenatal diagnosis: 2010Mark I Evans, Michael Kilpatrick
Current Opinion in Drug Discovery & Development|December 18, 2004
Purine nucleoside phosphorylase inhibitors in T-cell malignanciesShanta Bantia, John Michael Kilpatrick
Nucleosides, Nucleotides & Nucleic Acids|January 28, 2006
Synthesis and pharmacokinetic and pharmacodynamic evaluation of the forodesine HCl analog BCX-3040Hollis S Kezar, J Michael Kilpatrick, Deborah Phillips, et al.
International Immunopharmacology|April 20, 2010
Potent orally bioavailable purine nucleoside phosphorylase inhibitor BCX-4208 induces apoptosis in B- and T-lymphocytes--a novel treatment approach for autoimmune diseases, organ transplantation and hematologic malignanciesShanta Bantia, Cynthia Parker, Ramanda Upshaw, et al.
International Immunopharmacology|April 12, 2003
Intravenous and oral pharmacokinetic study of BCX-1777, a novel purine nucleoside phosphorylase transition-state inhibitor. In vivo effects on blood 2'-deoxyguanosine in primatesJ Michael Kilpatrick, Philip E Morris, David G Serota, et al.
AJNR. American Journal of Neuroradiology|April 17, 2025
Remote Robotic Neurointervention: Overcoming Procedural and Connectivity ChallengesGary R Duckwiler, Charles B Beaman, Michael Kilpatrick, et al.
Blood|April 30, 2010
Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemiaKumudha Balakrishnan, Dushyant Verma, Susan O'Brien, et al.
Pageof 1